

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

OVTOKO

RRID:CVCL_3117

Type: Cell Line

Proper Citation

JCRB Cat# NIHS0301, RRID:CVCL_3117

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3117

Proper Citation: JCRB Cat# NIHS0301, RRID:CVCL_3117

Description: Cell line OVTOKO is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian clear cell adenocarcinoma

Defining Citation: [PMID:7535723](#), [PMID:9328139](#), [PMID:11121861](#), [PMID:15677628](#), [PMID:17671176](#), [PMID:20081105](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22705003](#), [PMID:23430509](#), [PMID:23839242](#), [PMID:24023729](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OVTOKO

Cross References: BTO:BTO_0003499, CLO:CLO_0037101, EFO:EFO_0006728, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:492, BioSample:SAMN03472861, BioSample:SAMN10987767, cancercellines:CVCL_3117, Cell_Model_Passport:SIDM00425, CGH-DB:331-2, Cosmic:1223318, Cosmic:1328067, Cosmic:1434895, Cosmic:1708379, Cosmic:1889263, Cosmic:2074248, Cosmic:2482705, Cosmic-CLP:1298365, DepMap:ACH-000663,

EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1298365, GEO:GSM416681, GEO:GSM459732, GEO:GSM659399, GEO:GSM827253, GEO:GSM887490, GEO:GSM888572, GEO:GSM1176282, GEO:GSM1670325, IARC_TP53:30142, JCRB:JCRB1048, JCRB:NIHS0301, JCRB:NIHS0343, LiGeA:CCL_135, LINCS_LDP:LCL-1528, PharmacDB:OVTOKO_1228_2019, PRIDE:PXD030304, Progenetix:CVCL_3117, Wikidata:Q54937039

ID: CVCL_3117

Vendor: JCRB

Catalog Number: NIHS0301

Record Creation Time: 20220427T221404+0000

Record Last Update: 20260913T005705+0000

Ratings and Alerts

No rating or validation information has been found for OVTOKO.

Warning: Discontinued: JCRB; NIHS0301

Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: JCRB; NIHS0343

Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. *Advanced biology*, 10(3), e00404.

Bird GH, et al. (2025) A triple-action PROTAC for wild-type p53 cancer therapy. *Cell reports. Medicine*, 6(12), 102467.

Ford PW, et al. (2025) RNF10 and RIOK3 facilitate 40S ribosomal subunit degradation upon 60S biogenesis disruption or amino acid starvation. *Cell reports*, 44(3), 115371.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

Nie H, et al. (2025) Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. *Cancer research*, 85(18), 3471.

Tsuchimochi S, et al. (2023) Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma. *Scientific reports*, 13(1), 20292.

Zhou W, et al. (2023) Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. *Cancer cell*, 41(4), 740.

Ferrari AJ, et al. (2023) H2Bub1 loss is an early contributor to clear cell ovarian cancer progression. *JCI insight*, 8(12).

Zundell JA, et al. (2021) Targeting the IRE1 α /XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers. *Cancer research*, 81(20), 5325.